NTEC - インテック・ファ―マ (Intec Pharma Ltd.) インテック・ファ―マ



symbol NTEC
会社名 Intec Pharma Ltd (インテック・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    医療関連(Health Care)
概要 事業概要 --   インテック・ファ―マはイスラエルのバイオ医薬品企業。臨床段階で、「アコ―ディオン・ピル」プラットフォ―ム技術による経口投与型薬剤の開発に従事。既に服用している薬剤の効果や安全性を高め、また胃を守る働きがある。主要パイプラインには「カルビドパ・レボドパ(AP-CDLD)」と「ザレプロン(AP-ZP)」を含む。本社はエルサレム。   Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which focuses on developing drugs based on its proprietary Accordion Pill platform technology. Its product pipeline includes four product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients; Accordion Pill Zaleplon, which is being developed for the treatment of insomnia, including sleep induction and the improvement of sleep maintenance; an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug which induces ulcers; and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol and tetrahydrocannabinol, which is being developed for various indications including low back neuropathic pain and fibromyalgia. The company was founded by Zvi Joseph in 2000 and is headquartered in Jerusalem, Israel.
本社所在地 12 Hartom Street Har Hotzvim Jerusalem 9777512 ISR
設立年月日 36800
市場名 NASDAQ Small Cap
ipoyear 2015年
従業員数 70人
url www.intecpharma.com
nasdaq_url https://www.nasdaq.com/symbol/ntec
終値(lastsale) 4.84
時価総額(marketcap) 160813781.92
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --



   Intec Pharma to Participate in Jefferies London Healthcare Conference  2019/11/13 12:00:00 Yahoo Finance
JERUSALEM, Nov. 13, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that Company management will participate in the Jefferies London Healthcare Conference. Mr. Meckler's presentation will be webcast live and will be accessible through
   Implied Volatility Surging for Intec Pharma (NTEC) Stock Options  2019/08/30 12:52:00 Zacks Investment Research
Investors need to pay close attention to Intec Pharma (NTEC) stock based on the movements in the options market lately.
   The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate  2019/07/27 18:32:10 Benzinga
Biotech stocks moved mostly sideways during the week, although there was a flurry of activity in the space. Earnings from the sector began to trickle in, with Bristol-Myers Squibb Co (NYSE: BMY ) reporting forecast-beating earnings. Intec Pharma Ltd (NASDAQ: NTEC ) and Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) lost much of their market value this week on clinical trial setbacks. The following are some of the key biotech catalysts in the upcoming week: Conferences 2nd Annual Biotechnology Congress: July 29-30 in Chicago. 8th International Conference on Stroke and Cerebrovascular Diseases: July 29-30 in Stockholm, Sweden. 27th International Congress on Cardiology and Medical Interventions: July 31-Aug. 1 in Chicago. Clinical Trial Readouts (mid-2019 releases) Immunic Inc (NASDAQ: IMUX ): interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis. Conatus Pharmaceuticals Inc (NASDAQ: CNAT ): 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis.
   Intec Shares Slammed As Advanced Parkinson's Disease Drug Combo Flunks Late-Stage Study  2019/07/22 14:15:46 Benzinga
Micro-cap Intec Pharma Ltd (NASDAQ: NTEC ) shares are plummeting on heavy volume Monday following a clinical trial readout from the company . What Happened Intec, a clinical-stage biotech that develops drugs based on its proprietary Accordion Pill platform technology, said top-line data from a pivotal Phase 3 trial dubbed ACCORDANCE did not achieve the primary endpoint. The study evaluated the safety and efficacy of the Accordion Pill – Carbidopa/Levodopa compared with immediate release Carbidopa/Levodopa for treating symptoms of advanced Parkinson's disease, with a reduction in daily OFF time being the primary endpoint. OFF periods are time when dopamine in the brain … Full story available on Benzinga.com
   Tetra Bio-Pharma: Diamond In The Rough  2019/05/23 15:18:25 Seeking Alpha
   Intec Pharma Granted European Patent  2019-05-20 PR Newswire
JERUSALEM , May 20, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the European Patent Office has granted the Company European Patent No. 2997953 titled, "DELIVERY DEVICE FOR ORAL INTAKE OF AN AGENT," and covers Intec's gastro-retenti…
   Intec Pharma to Participate in the HC Wainwright Global Life Sciences Conference  2019-04-01 PR Newswire
JERUSALEM , April 1, 2019 /PRNewswire/ --Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate in the upcoming HC Wainwright Global Life Sciences Conference. HC Wainwright Global Life Sciences Conference Dat…

 関連キーワード  (― 米国株 インテック・ファ―マ NTEC Intec Pharma Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)